Title: Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a
prognostic biomarker and therapeutic target in gastric cancer
Version: 1 Date: 14 Feb 2025
Reviewer:  Jing-Ping Yuan
Reviewer's report:
The manuscript presents a comprehensive bioinformatics analysis of glycometabolism-related
genes in gastric cancer (GC), identifying PLOD2 as a key prognostic biomarker and therapeutic
target. The study integrates transcriptomic data from multiple databases, functional assays, and
pathway enrichment analyses to elucidate the role of PLOD2 in tumor progression, immune
evasion, and therapeutic resistance. The findings are robust and well-supported by the data.
However, there are a few areas where minor improvements could be made to enhance the clarity
and impact of the manuscript. Therefore, I recommend minor revisions.
1.Expand the discussion to include a critical analysis of the limitations and potential biases in the
study. Discuss potential future directions, including the validation of PLOD2 as a therapeutic
target in clinical trials.
2.Include a more detailed discussion of the potential clinical applications of targeting PLOD2,
particularly in combination with other therapies such as immune checkpoint inhibitors.
3.Update the literature review to include more recent studies on glycometabolism and PLOD2
in GC and other cancers.
4.Simplify some of the figure panels and provide more detailed legends to enhance clarity.
5.Edit the manuscript for conciseness and correct any grammatical errors.
6.Provide a more detailed explanation of the statistical methods used in the bioinformatics
analysis, particularly the machine learning algorithms.
7.Update the literature review to include more recent studies on glycometabolism and PLOD2
in cancer biology.
Title: Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a
prognostic biomarker and therapeutic target in gastric cancer
Version: 1 Date: 14 Feb 2025
Reviewer:  Jing-Ping Yuan
Reviewer's report:
The manuscript presents a comprehensive bioinformatics analysis of glycometabolism-related
genes in gastric cancer (GC), identifying PLOD2 as a key prognostic biomarker and therapeutic
target. The study integrates transcriptomic data from multiple databases, functional assays, and
pathway enrichment analyses to elucidate the role of PLOD2 in tumor progression, immune
evasion, and therapeutic resistance. The findings are robust and well-supported by the data.
However, there are a few areas where minor improvements could be made to enhance the clarity
and impact of the manuscript. Therefore, I recommend minor revisions.
1.Expand the discussion to include a critical analysis of the limitations and potential biases in the
study. Discuss potential future directions, including the validation of PLOD2 as a therapeutic
target in clinical trials.
2.Include a more detailed discussion of the potential clinical applications of targeting PLOD2,
particularly in combination with other therapies such as immune checkpoint inhibitors.
3.Update the literature review to include more recent studies on glycometabolism and PLOD2
in GC and other cancers.
4.Simplify some of the figure panels and provide more detailed legends to enhance clarity.
5.Edit the manuscript for conciseness and correct any grammatical errors.
6.Provide a more detailed explanation of the statistical methods used in the bioinformatics
analysis, particularly the machine learning algorithms.
7.Update the literature review to include more recent studies on glycometabolism and PLOD2
in cancer biology.
Please review this paper.
user
Title: Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a
prognostic biomarker and therapeutic target in gastric cancer
Version: 1 Date: 14 Feb 2025
Reviewer:  Jing-Ping Yuan
Reviewer's report:
The manuscript presents a comprehensive bioinformatics analysis of glycometabolism-related
genes in gastric cancer (GC), identifying PLOD2 as a key prognostic biomarker and therapeutic
target. The study integrates transcriptomic data from multiple databases, functional assays, and
pathway enrichment analyses to elucidate the role of PLOD2 in tumor progression, immune
evasion, and therapeutic resistance. The findings are robust and well-supported by the data.
However, there are a few areas where minor improvements could be made to enhance the clarity
and impact of the manuscript. Therefore, I recommend minor revisions.
1.Expand the discussion to include a critical analysis of the limitations and potential biases in the
study. Discuss potential future directions, including the validation of PLOD2 as a therapeutic
target in clinical trials.
2.Include a more detailed discussion of the potential clinical applications of targeting PLOD2,
particularly in combination with other therapies such as immune checkpoint inhibitors.
3.Update the literature review to include more recent studies on glycometabolism and PLOD2
in GC and other cancers.
4.Simplify some of the figure panels and provide more detailed legends to enhance clarity.
5.Edit the manuscript for conciseness and correct any grammatical errors.
6.Provide a more detailed explanation of the statistical methods used in the bioinformatics
analysis, particularly the machine learning algorithms.
7.Update the literature review to include more recent studies on glycometabolism and PLOD2
in cancer biology.
assistant